% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • biobottom biobottom Sep 27, 2013 6:52 PM Flag

    Kadcyla beats Herceptin: Take note

    By Simeon Bennett - Sep 27, 2013 12:43 PM PT
    “Few drugs have been able to achieve both improved progression-free survival and a better toxicity profile,” Hans Wildiers, who led the study at the University Hospitals Leuven in Belgium, said in a statement. The results show Kadcyla “has the potential to be a new treatment paradigm for this group of patients who currently have few options.”
    Kadcyla, also known as T-DM1, is a so-called antibody-drug conjugate that combines Herceptin with a cell-killing drug called DM1 using technology licensed from Waltham, Massachusetts-based ImmunoGen Inc. (IMGN) that shepherds the drug directly to the cancer cell, reducing collateral damage to healthy cells.

    Sentiment: Buy

2.82-0.05(-1.74%)Sep 23 4:00 PMEDT